EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly recognized entity in the 2022 International Consensus Classification (ICC) of mature lymphoid neoplasms. It ...
Companies are engineering B cells to produce gene-encoded medicines, but clinical proof of concept is needed to convince the doubters that this platform can deliver. Early observations from the ...
About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...
Antibody-mediated rejection (ABMR) remains the leading immunological cause of kidney allograft loss, yet its humoral origins are incompletely understood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results